Novartis CEO Calms Concerns Over Zolgensma launch
Executive Summary
The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.
You may also be interested in...
One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.
Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
Novartis's Ofatumumab Pursues Entrenched Competitors In MS
Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports